{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:25:12Z","timestamp":1790601912914,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijcard.2025.133608","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:50:26Z","timestamp":1752580226000},"page":"133608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program"],"prefix":"10.1016","volume":"439","author":[{"given":"Chiara","family":"Tognola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Cristina Myriam","family":"Intravaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Brioschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Algeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atea","family":"Shkodra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Scium\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giannattasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"47","key":"10.1016\/j.ijcard.2025.133608_bb0005","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12933-023-01921-5","article-title":"Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study","volume":"22","author":"Kristensen","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"10.1016\/j.ijcard.2025.133608_bb0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2024.06.035","article-title":"Triglyceride levels, Alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome","volume":"84","author":"Zahger","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.ijcard.2025.133608_bb0025","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"9500","key":"10.1016\/j.ijcard.2025.133608_bb0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet Lond. Engl."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2025.133608_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am. Heart J."},{"issue":"9567","key":"10.1016\/j.ijcard.2025.133608_bb0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ijcard.2025.133608_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2022.11.008","volume":"257","author":"Nishizaki","year":"2023","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ijcard.2025.133608_bb0060","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/eurheartj\/ehab771","article-title":"Extreme cardiovascular risk-do we need a new risk category?","volume":"43","author":"Dyrbu\u015b","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133608_bb0070","doi-asserted-by":"crossref","unstructured":"Darkes MJM, Poole RM, Goa KL. Ezetimibe. Am. J. Cardiovasc. Drugs Drugs Devices Interv. 2003;3(1):67\u201376; discussion 77\u201378.","DOI":"10.2165\/00129784-200303010-00007"},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"38","key":"10.1016\/j.ijcard.2025.133608_bb0080","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.ijcard.2025.133608_bb0085","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133608_bb0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2025.133608_bb0095","first-page":"242","article-title":"Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Prevalencia de hipertrigliceridemia en adultos y factores cardiometab\u00f3licos asociados. Estudio SIMETAP-HTG","volume":"32","author":"Ruiz-Garc\u00eda","year":"2020","journal-title":"Clin. Investig. Arterioscler."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133608_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40119-020-00170-x","article-title":"Prevalence of US adults with triglycerides\u2265150 mg\/dl: NHANES 2007-2014","volume":"9","author":"Fan","year":"2020","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.ijcard.2025.133608_bb0105","first-page":"A34","article-title":"Residual risk in cardiac rehab: can we reduce-it more? Eligi-bility for icosapent ethyl in patients attending cardiac rehabilitation","volume":"106","author":"Gaine","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2025.133608_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.04.193","article-title":"Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome","author":"Cordero","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2025.133608_bb0115","article-title":"Analysis of residual risk and recurrent event trends following acute coronary syndrome: a cohort study [internet]","author":"Shuey","year":"2024","journal-title":"medRxiv"},{"issue":"17","key":"10.1016\/j.ijcard.2025.133608_bb0120","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"228","key":"10.1016\/j.ijcard.2025.133608_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"1","author":"Nosaka","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2025.133608_bb0130","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjmed.2021.03.014","article-title":"Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction","volume":"134","author":"Mason","year":"2021","journal-title":"Am. J. Med."},{"issue":"15","key":"10.1016\/j.ijcard.2025.133608_bb0135","first-page":"1863","article-title":"Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis","volume":"31","author":"Dinu","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133608_bb0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5551\/jat.50658","article-title":"Prevention of cardiovascular events with Omega-3 polyunsaturated fatty acids and the mechanism involved","volume":"27","author":"Watanabe","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.ijcard.2025.133608_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117388","article-title":"Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: a secondary analysis of a randomized trial","volume":"387","author":"Hariri","year":"2023","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.ijcard.2025.133608_bb0150","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the Management of Patients with Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325006515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325006515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:50:41Z","timestamp":1757911841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325006515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"alternative-id":["S0167527325006515"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133608","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"133608"}}